Verona Pharma Announces US FDA Approval of Ohtuvayre™ …
Jun 26, 2024 · LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
Verona Pharma News and Resources
Jan 7, 2025 · Stay updated with Verona Pharma's latest news and resources. Access materials to follow our progress in developing treatments for respiratory diseases and understand our journey and impact in tackling these conditions.
News & SEC Filings - Verona Pharma
Jan 7, 2025 · Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Verona Pharma Press Releases & Updates
Jan 7, 2025 · Follow Verona Pharma’s latest updates through our press releases. Stay informed on financial results, strategic financing, clinical developments, and upcoming presentations as we advance respiratory treatments.
Verona Pharma | Innovative Respiratory Treatments
Jan 7, 2025 · Verona Pharma develops novel treatments like ensifentrine in COPD. Future development is focused on chronic lung diseases such as COPD, asthma, and cystic fibrosis. Explore our advancements, patient insights, and latest investor news
Verona Pharma Reports Third Quarter 2024 Financial Results and …
Nov 4, 2024 · LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2024, and provides a corporate update.
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE …
Sep 30, 2024 · LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and two posters on analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD ...
Investor Relations | Verona Pharma
Jan 7, 2025 · Learn about Verona Pharma's innovative respiratory treatments and latest financial updates. Explore our investor presentation, recent results, and news for insights into our progress and company performance.
Verona Pharma Announces $650 Million Strategic Financing with …
May 9, 2024 · The agreements provide non-dilutive capital and additional financial flexibility ahead of Verona Pharma’s planned US launch of ensifentrine and will support the Company’s continued growth.
Verona Pharma Reports Second Quarter 2024 Financial Results …
Aug 8, 2024 · LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2024, and provides a corporate update.